(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Insane Realities That Will Make You Reconsider How you might interpret History - 2Moscow accuses Berlin of stifling the opposition
- 3Family-Accommodating Snow Sports Experiences
- 4Revvity says it will exceed 2025 profit forecast range
- 5AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- Commonsense Ways to work on Your Funds with a Restricted Pay
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- California is completely free of drought for the first time in 25 years
- Danish warship sunk by famed British admiral discovered after 225 years
- The Following Huge Thing: 5 Progressive Tech New businesses
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- The Best Computer games for Multiplayer Fun
- Exploring the Main Year of Life as a parent: Individual Encounters
- Becoming Familiar with an Unknown dialect: My Language Learning Excursion
